-
Some health care facilities are finding that video cameras inside and outside the facility are allowing them to reduce crime and maintain security staffing even as the facility grows.
-
Six new reports issued by the AAAHC Institute for Quality Improvement (AAAHC Institute), a not-for-profit subsidiary of the Accreditation Association for Ambulatory Health Care (AAAHC), offer insights to enhance the quality and efficiency of some of the most common outpatient procedures.
-
Researchers report that, compared with conventional sedation, balanced propofol sedation (BPS) using propofol with midazolam and meperidine provided higher provider satisfaction, better patient cooperation, and similar adverse event profiles in patients undergoing therapeutic endoscopic procedures.
-
In a representative sample of Americans, about a third reported getting less than 7 hours of sleep on average, about half reported snoring, and nearly 5% reported falling asleep while driving in the past month.
-
An encounter with a critically ill simulated "patient" was used successfully to analyze the communication skills of experienced physicians and identify areas for improving communication behaviors.
-
The treatment of atopic dermati-tis (ATD) usually is initiated with topical steroids (TPS). Because ATD is a chronic remitting and relapsing disorder and may occupy a large cutaneous area, exposure to TPS can be extensive.
-
-
Severe Vitamin D deficiency appears to worsen dementia and supplementation may be beneficial.
-
As reported in 2003, the world bank began funding a project to train giant pouched Gambian rats to sniff out tuberculosis (TB) in sputum specimens in sub-Saharan Africa. Rats have been successfully trained to target landmines, and using a similar training/reward technique, pilot data suggested that rats could be trained to detect TB in respiratory specimens.
-
A new antidepressant that combines selective serotonin reuptake inhibition with partial agonism of the 5-HT1A receptor has been approved by the FDA. Vilazodone is marketed by Trovis Pharmaceuticals as Viibryd(TM).
